HomeBusiness & MoneyNKGen doses first patient in Phase 1/2a Alzheimer's study (NASDAQ:NKGN)

NKGen doses first patient in Phase 1/2a Alzheimer’s study (NASDAQ:NKGN)


juststock

NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy SNK01 in the treatment of moderate Alzheimer’s disease, AD.

The biotech company said the Phase 1 portion of the study will



Source link

RELATED ARTICLES

Most Popular

Recent Comments